| HOME >> BIOLOGY >> TECHNOLOGY |
BRANFORD, Conn., Sept. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that Timothy M. Shannon, M.D., has been appointed President and Chief Executive Officer, effective immediately, replacing Dr. Frank Armstrong. Dr. Armstrong will remain with the Company through the end of 2007, to assist with the transition, and will continue on CuraGen's Board of Directors until the Annual Stockholders Meeting in May 2008.
Dr. Shannon has extensive experience related to the research, development and commercialization of novel therapeutics, and has served as Executive Vice President of Research and Development and Chief Medical Officer of CuraGen since September 2002. During the past five years, CuraGen has refined its portfolio of early stage assets into a therapeutic pipeline under Dr. Shannon's leadership with the focus now on three oncology programs including velafermin, belinostat and CR011-vcMMAE.
"Tim has done an outstanding job of leading CuraGen's drug pipeline through development, and we are delighted that he is assuming the role of President and CEO of CuraGen at a time when there is significant potential for CuraGen to bring one or more of its drugs into Phase III in 2008," commented Mr. Robert E. Patricelli, Chairman of the Board of CuraGen.
"At the same time," Mr. Patricelli further commented, "I would like to
thank Frank on behalf of the entire Board of Directors for stepping up from
the board in March 2006 to become CEO at a transformational time in the
history of CuraGen. During his time as CEO, CuraGen monetized its
investment in 454 Life Sciences, focused the Company around its 3 lead
products and st
'/>"/>
| SOURCE CuraGen Corporation Copyright©2007 PR Newswire. All rights reserved |